Etrasimod – second generation S􀍷P receptor modulators in ulcerative colitis therapy

Česká verzia

Authors: M. Lukáš
Authors place of work: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2024; 78(5): 415-416
Category: Drug Profile
doi: https://doi.org/10.48095/ccgh2024415

Zdroje

1. Sandborn JW, Vermeire S, Peyrin-Biroulet L et al. Etrasimod as induction and maintenance for ulcerative colitis (ELEVATE): two randomised, double blind, placebo controlled, phase 3 study. Lancet 2023; 401 (10383): 1159–1171. doi: 10.1016/S0140-6736 (23) 00061-2.

2. Ruguiero M, Siegmund B, Yarur AJ et al. Etrasimod for the treatment of ulcerative colitis: Analysis of infection event from the ELEVATE UC programme. J Crohns Colitis. In press 2024. doi: 10.1093/ecco-jcc/jjae060.

3. Pyerin-Biroulet L, Dubinsky M, Sands BE et al. Efficacy and safety of Etrasimod in patients with moderately to severely active isolated proctitis: Results from the phase 3 ELEVATE UC clinical programme. J Crohn’s Colitis 2024; 18 (8): 1270–1282. doi: 10.1093/ecco-jcc/jjae038.

prof. MUDr. Milan Lukáš, CSc., AGAF

Klinické a výzkumné centrum pro střevní záněty

Klinické centrum ISCARE a. s. a 1. LF UK v Praze

Českomoravská 19

190 00 Praha 9

milan.lukas@email.cz